# CLAIMS

1. An injectable composition in the form of a liquid having a solvent or in the form of a solid, the injectable composition comprising: 5α-androstane-3β,5,6β-triol and at least one soluble excipient, wherein the at least one soluble excipient includes hydroxypropyl-β-cyclodextrin.

2. The injectable composition of claim 1, wherein the weight ratio of 5α-androstane-3β,5,6β-triol to hydroxypropyl-β-cyclodextrin is 1-20: 40-500.

3. The injectable composition of claim 1 or claim 2, wherein the soluble excipient further comprises an isotonic adjusting agent and/or a freeze drying filler.

4. The injectable composition of claim 3, wherein the isotonic adjusting agent is selected from the group consisting of: sodium chloride, glucose, mannitol, lactose, xylitol, sorbitol, maltitol and mixtures thereof.

5. The injectable composition of claim 3, wherein the freeze-drying filler is selected from the group consisting of: sodium chloride, glucose, mannitol, lactose, xylitol, sorbitol, maltitol and mixtures thereof.

6. The injectable composition according to any one of claims 1 to 5, wherein the solvent is selected from the group consisting of: propanediol, ethanol, polyethylene glycol 400, polyethylene glycol 200, glycerol, water and mixtures thereof.

7. The injectable composition according to any one of claims 3 to 5, wherein the injectable composition consists of (by weight): 1-20 parts of the 5α-androstane-3β,5,6β-triol, 40-500 parts of the hydroxypropyl-β-cyclodextrin, 1-100 parts of the isotonic adjusting agent, 0-200 parts of the freeze drying filler, and 0-2000 parts of the solvent.

8. A method for preparing the injectable composition of claim 1, comprising steps of:

(a) dissolving hydroxypropyl-β-cyclodextrin, 5α-androstane-3β, 5,6β-triol and additional soluble excipients in water for injection in sequence to obtain a raw injectable solution; and

(b1) subjecting the raw injectable solution to decolorization, depyrogenation, filtration and sterilization to obtain the injectable composition; or

(b2) subjecting the raw injectable solution to decolorization, depyrogenation, filtration and filling a filtrate produced by the filtration into an ampoule, followed by freeze drying to obtain a freeze dried powder; or

(b3) subjecting the raw injectable solution to decolorization, depyrogenation, filtration and spray drying a filtrate produced by the filtration to produce a powder,